We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers should establish a company task force of upper management and quality personnel to prevent drug shortages, according to new good practice guidelines developed by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Read More
The Department of Justice is investigating a Phase III study of AstraZeneca’s (AZ) heart drug Brilinta, which analysts and experts say could revolve around allegations of data falsification. Read More
A multidistrict mass tort suit filed July 1 in Illinois accuses Bristol-Myers Squibb and Sanofi of recklessly promoting the benefits of their blockbuster blood-thinner Plavix, despite knowing it was “defectively designed, inadequately tested, dangerous to human health, and lacked proper warnings as to dangers associated with its use.” Read More